QualityStocks'  Instablog

Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • ARCA biopharma (ABIO) receives Patent for Methods of Treatment with Bucindolol 0 comments
    Dec 30, 2011 5:16 PM | about stocks: ABIO

    ARCA biopharma Inc., a biopharmaceutical company developing genetically targeted therapies for cardiovascular diseases, has been awarded a patent from the U.S. Patent and Trademark Office (USPTO) for the company’s methods of treating patients with bucindolol based on genetic targeting and focused on a specific genotype (homozygous wildtype for Deletion 322-325 in the alpha-2C adrenergic receptor).

    The patent entitled “Methods for Treatment with Bucindolol Based on Genetic Targeting” provides patent protection in the United States for the company’s approach to treating patients with bucindolol.

    Dr. Michael Bristow, CEO of ARCA biopharma, emphasized the challenges surrounding cardiovascular diseases and how new therapies can address these challenges.

    “We are obviously pleased with the USPTO’s issuance of this patent, which we believe extends our pharmacogenetic intellectual property protection around bucindolol,” Dr. Bristow stated in the press release. “Chronic cardiovascular diseases continue to be a major health care problem, and among the challenges to improving care is the uncertainty of patient responses to drug treatment. We believe new therapies that include a simple test to identify a substantial subpopulation of patients more likely to benefit have the potential to alleviate some of the problems encountered with the current standard of pharmacotherapy, where all members of a disease cohort, including those who will not respond, are treated.”

    Dr. Bristow said bucindolol is exclusive in its ability to lower the hormone responsible for increasing blood pressure and rate and depth of breathing, as well as raising blood sugar levels and decreasing activity of the intestines.

    “A unique pharmacologic property of bucindolol is norepinephrine lowering, and bucindolol’s heart failure clinical responses demonstrated in a large phase 3 clinical trial (OTCPK:BEST) were modulated by this important effect. … Accordingly, we believe prospective knowledge … allows for prediction of the degree of norepinephrine lowering by bucindolol in an individual patient,” Dr. Bristow concluded.

    For more information visit arcabiopharma.com

    Please see disclaimer on the QualityStocks website: disclaimer.qualitystocks.net

    Stocks: ABIO
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.